ATATcH Alternating Treatment Plans for Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction
chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone
for the initial treatment of patients with advanced lung or head and neck cancers.